Scott Skibo, MD currently serves as the Chief Medical Officer for Eon Health.  Prior to joining Eon Health in 2021, he has presented regularly at national scientific meetings focused on interventional pulmonology and lung cancer.  After finishing his pulmonary and critical care fellowship at Yale University in 2001, he gained over 20 years of experience in the thoracic oncology clinical space.  He co-developed the first system-wide incidental pulmonary nodule program in the United States in 2012.  He now leads the clinical team at Eon that oversees the quality and clinical outcomes for over 1000 US-based hospitals- helping to ensure the timely care for over 1 million patients per year.

Ivan Vlahović works as a general surgeon at the Surgery Clinic of the Clinical Hospital Center Osijek, at the Department of Abdominal Surgery. His field of interest is colorectal and gastrointestinal surgery, especially colorectal and gastric cancer surgery. His scientific field of interest is colorectal cancer genetics and epigenetics. He earned his PhD in 2024., and the thesis he defended was named ‘The association between CDX2 expression loss and mismatch repair proteins expression in colorectal cancer patients’. He would like to present his results at this conference. 

Dr. Huang is currently an Associate Research Fellow at Tzu Chi Hospital in Taiwan. He has many years of experience as an oncologist at the Center for Prevention and Therapy of Gynecological Cancers within the Department of Research. His work focuses on the development and molecular mechanisms of high-grade serous carcinoma (HGSC), and he regularly publishes research articles and presents his findings at national and international scientific conferences. His group has conducted a series of studies on ovulation-associated HGSC initiation and has developed multiple cell and animal models to investigate HGSC pathogenesis, contributing important tools and insights to the field.

Professor/Dr. Besarion Partsvania is the head of the Bio-cybernetics department of the Institute of Cybernetics of the Georgian Technical University. He possesses extensive expertise in the field of biomedical research. In particular, he was among the first to use infrared tomography to diagnose kidney and prostate cancer. His most recent research shows that prostate aggression can be accurately assessed using the infrared imaging approach. 

Gennady Machak is an oncologist at the Priorov Institute of Traumatology and Orthopedics, Moscow, Russia. He has 25 years of experience as an oncologist specializing in musculoskeletal tumors at the Blokhin Cancer Research Center and 12 years at the Priorov Institute. He has been a member of EMSOS since 2000. He regularly publishes in musculoskeletal oncology journals and regularly presents data at national and international scientific conferences. In recent years, his group has developed new approaches to non-surgical treatment of locally advanced and inoperable benign bone tumors.

Yuki Yoshimatsu is the Project Leader at Tochigi Cancer Center Research Institute and a Visiting Researcher at the National Cancer Center Research Institute, Japan. She specializes in translational cancer research, focusing on biomarkers and drug development. She has established over 100 patient-derived cancer models and actively contributes to rare cancer research.

Layah Liz Jacob is a PhD Scholar at CHRIST (Deemed to be University), Bengaluru, India under the guidance of Dr. Anuradha S. She holds an M.Sc in Clinical psychology from the same university and has been actively involved in the field of women and trauma for over 6 years. Alongside her supervisor, she was also a part of a collaborative research project with Miami university, focusing on enhancing life after cancer survivorship. Her doctoral research explores the interplay of existentialism, mortality awareness and spirituality in fostering post traumatic growth among cancer survivors, aiming to deepen understanding and support for their psychological recovery

Sanju Mannumadam Venugopal is based out of California, USA. He is working as Senior Manager at a decentralized clinical trial technology company. Has a bachelor’s degree in Bioinformatics and an MBA in Information Systems. Has 13+ years’ of experience in Technology & Compliance in healthcare and pharmaceutical domain. He is an independent researcher in artificial intelligence (AI) and healthcare. Has published research papers in various journals on topics such as AI in oncology medical image analysis, generative AI in healthcare, responsible AI in healthcare etc. He is an active member of IEEE working on standards for developing LLM Agentic AI interface. He is a member of ISPE. He has reviewed paper in reputed journal such as “Expert System” related to medical AI research. He is an Elsevier-certified peer reviewer.

Yunhee Jeong, Ph.D., is a Senior Scientist II at AbbVie with over 15 years of expertise in immunology and pre-clinical safety. She holds a Ph.D. in Functional Genomics from Dong-A University in South Korea. Dr. Jeong completed postdoctoral fellowships at University of Pennsylvania and Yonsei University, where she lead research on molecular mechanisms of inflammation, immune responses, and discovery of immunoregulatory pathways, resulting in multiple publications and patents. At AbbVie, she led the establishment and optimization of in vitro immunogenicity platforms, successfully integrating them into the pipeline screening funnel to derisk drug candicates. Currently, she is expanding her capabilities in establishing a foundation for comprehensive data management to enhance AbbVie’s research capabilies. Yunhee Jeong, Ph.D., is a Senior Scientist II at AbbVie with over 15 years of expertise in immunology and pre-clinical safety. She holds a Ph.D. in Functional Genomics from Dong-A University in South Korea. Dr. Jeong completed postdoctoral fellowships at University of Pennsylvania and Yonsei University, where she lead research on molecular mechanisms of inflammation, immune responses, and discovery of immunoregulatory pathways, resulting in multiple publications and patents. At AbbVie, she led the establishment and optimization of in vitro immunogenicity platforms, successfully integrating them into the pipeline screening funnel to derisk drug candicates. Currently, she is expanding her capabilities in establishing a foundation for comprehensive data management to enhance AbbVie’s research capabilies. 

Weiting Huang is a Chief Physician in Radiation Oncology at China Medical University Affiliated Tumor Hospital, Shenyang, China. With over 10 years of experience in tumor radiation therapy, she specializes in advanced radiation techniques such as IMRT, TOMO, and CyberKnife. She has developed over 300 personalized radiation treatment plans annually and has contributed to 8 national and provincial clinical research projects. Her work focuses on enhancing tumor treatment outcomes through multimodal imaging fusion and dose optimization, advancing the clinical translation of precision radiation therapy techniques.

Mario Perez-Medina is an oncology researcher at the Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas and Asociación Para Evitar la Ceguera en México. He specializes in bioinformatics analysis of next-generation sequencing (NGS) data, with a focus on understanding mechanisms of drug resistance in lung cancer. His research includes transcriptomic analysis of intrinsic resistance in lung adenocarcinoma, particularly the role of drug-tolerant persister (DTP) cells and the involvement of long non-coding RNAs (lncRNAs) and CD74 in therapeutic resistance. His work integrates genomic datasets from in-house experiments and public repositories to unravel molecular mechanisms of cancer progression and immune response. He has presented research findings at national and international conferences and has authored multiple peer-reviewed publications in oncology, molecular biology, and bioinformatics.

Lidiia Bolhova,  professor of National Cancer Institute, Kyiv, Ukraine. she was involved in the morphological diagnosis of many oncological diseases. she has been working at the institute for more than 50 years. Our scientists and she wrote 3 monographs (one of them on the histogenesis of lung cancer, 2013) and 7 manuals for morphologists. she have been studying   the problem of lung cancer for many years. she is  President of Ukrainian Association Cytopathology.

Clement Kwabena Apaw is a distinguished Ghanaian public health professional specializing in healthcare research, data analysis, and epidemiology. As a Senior Health Data Analyst and Health Tutor at Ghana’s Ministry of Health, he has played a pivotal role in shaping data-driven healthcare strategies. With a strong commitment to capacity building, Clement has trained over 1,200 health professionals and developed impactful training programs to optimise data management and improve health outcomes.

He holds a PhD in Epidemiology & Health Statistics at Southern Medical University, where he earned his Master of Public Health (MPH). His academic journey includes a Postgraduate Diploma in Education from the University of Education, Ghana, a Bachelor of Science (BSc) in Information and Communication Technology (ICT) from Presbyterian University, Ghana, a Diploma in Health Information (technical Officer) from College of Health and Well-being, Kintampo, and a Certificate in Health Administration from the Ghana Institute of Management and Public Administration (GIMPA).

Clement’s research interests span cancer screening, perinatal health, prostate cancer prevention, maternal and child health, and health technology. As an active contributor to the scientific community, he has published in respected journals and serves as a peer reviewer. His expertise extends to advanced data analysis tools such as Power BI, R, STATA, and ArcGIS Pro.

Driven by a passion for strengthening Ghana’s health systems, Clement is dedicated to advancing research, fostering data-driven decision-making, and leading capacity-building initiatives that enhance healthcare delivery.

Shuai Tan | MD, PhD, Physician-Scientist Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing, China
Obtained the doctoral degree from Karolinska Institutet. Member of SITC (Society for Immunotherapy of Cancer); Young Editorial Board Member of Brain Network Disorders (Selected by Excellence Action Plan for China STM Journals); Reviewer for Front. Med., Front. Pharmacol., Curr. Neuropharmacol..He is the member of Dr. Wanling Sun's Clinical and Research team (Dr. Wanling Sun, PI and Director of the Hematology Department at Xuanwu Hospital), primarily focusing on research related to hematology immunology.
Long-term focus on hematological disease diagnosis/treatment, platelet mitochondrial energy metabolism immune crosstalk function, immune cells, and clinical/mechanistic research in atherosclerosis. The researches has received support from multiple funding sources, including national-level and provincial/ministerial-level grants. He elucidated novel mechanism where platelet-released PF4 modulates T-cell immune response crosstalk, providing a potential intervention target for developing next-gen platelet therapeutics and improving hematopoietic diseases. First proposed the "Aplastic Anemia-T Cell-Platelet" interaction theory. The team's research objective is to elucidate the role of platelet regulation of immune cell function and energy metabolism in the pathogenesis of hematological diseases, thereby developing next-generation platelet-based immunotherapeutic agents, which will help improve patient prognosis, enhance quality of life, alleviate economic burden, and generate social and economic benefits.

Dr. Jamila Khalid Al Azhri is a highly accomplished Consultant Oncoplastic Breast Surgeon, formerly serving as the Head of the Breast & Endocrine Section at King Fahad Specialist Hospital in Dammam. She currently leads the Breast Surgery Service within the Eastern Health Cluster in Saudi Arabia. Dr. Al Azhri holds certifications from both the Saudi and Arab Boards of General Surgery, and has completed prestigious fellowships in Breast Surgical Oncology at the University of Miami’s Miller School of Medicine and Jackson Memorial Hospital (USA), Oncoplastic and Reconstructive Breast Surgery at the Paris Breast Institute (France), and Breast Cancer Research at Roswell Park Cancer Institute in Buffalo, New York (USA). She is an active member of The American Society of Breast Surgeons and The Saudi Society of Breast & Endocrine Surgeons. A passionate educator and researcher, Dr. Al Azhri founded the BESA Annual Conference in 2020 and the BLOSS Surgical Course in 2019. Her academic contributions include numerous peer-reviewed publications focused on breast cancer prevention and treatment, alongside frequent oral and poster presentations at leading national and international conferences such as SSBES, SABCS, ASCO, SSO, ESSO, and ASBrS.

Sanju Mannumadam Venugopal is based out of California, USA. He is working as Senior Manager at a decentralized clinical trial technology company. Has a bachelor’s degree in Bioinformatics and an MBA in Information Systems. Has 13+ years’ of experience in Technology & Compliance in healthcare and pharmaceutical domain. He is an independent researcher in artificial intelligence (AI) and healthcare. Has published research papers in various journals on topics such as AI in oncology medical image analysis, generative AI in healthcare, responsible AI in healthcare etc. He is an active member of IEEE working on standards for developing LLM Agentic AI interface. He is a member of ISPE. He has reviewed paper in reputed journal such as “Expert System” related to medical AI research. He is an Elsevier-certified peer reviewer.

Aswathy Kooriyattil is a  doctors working in general medical department at King’s college hospital London.With a strong clinical interest in oncology and cancer research,she was  actively involved in projects aimed at improving cancer diagnosis, treatment, and patient outcomes. She was committed to contributing to evidence-based practice through ongoing research and collaboration within multidisciplinary teams.

Arjun Raj is a doctor  working in general medical department at King’s college hospital London.With a strong clinical interest in oncology and cancer research,
he was actively involved in projects aimed at improving cancer diagnosis, treatment, and patient outcomes. He was committed to contributing to evidence-based practice through ongoing research and collaboration within multidisciplinary teams.

Dr. Lakshmi Revi, currently working in the General Medicine Department at King’s College Hospital, London. She has a strong interest in internal medicine, oncology, and research-based clinical practice. Her clinical experience spans both the NHS and international healthcare systems, and she has been actively involved in quality improvement initiatives. She is passionate about combining clinical care with academic development.

Scott Skibo, MD currently serves as the Chief Medical Officer for Eon Health.  Prior to joining Eon Health in 2021, he has presented regularly at national scientific meetings focused on interventional pulmonology and lung cancer.  After finishing his pulmonary and critical care fellowship at Yale University in 2001, he gained over 20 years of experience in the thoracic oncology clinical space.  He co-developed the first system-wide incidental pulmonary nodule program in the United States in 2012.  He now leads the clinical team at Eon that oversees the quality and clinical outcomes for over 1000 US-based hospitals- helping to ensure the timely care for over 1 million patients per year.